Name

NSABP Foundation

Legal name

NSABP Foundation, Inc.

Website

https://nsabp.org

Company type

Private

Founded year

1957

Operating status

Operating

Headcount range

101–250 employees

Short description

NSABP Foundation is a Pittsburgh-based 501(c)(3) nonprofit academic research organization that designs and conducts breast and colorectal cancer clinical trials through a 500+ site network, leveraging a biospecimen bank of 87,000+ patients, funded by the NCI, industry sponsors, and philanthropy.

Ownership category

akta.pro rank

Product category

Oncology Clinical Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Clinical Trial Site Operations & Study Coordination (HLAGACAE), Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA), Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH)

Keywords

• Clinical trials research
• Oncology clinical studies
• Breast cancer research
• Colorectal cancer trials
• Academic research organization

Headquarters

HQ city

Pittsburgh

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure

Revenue model

1. Government-Funded Clinical Trials (NCI NCTN): NSABP Foundation operates as part of the NCI National Clinical Trials Network (NCTN) and receives government funding to design and conduct federally-sponsored clinical trials in breast and colorectal cancer.
2. Industry-Sponsored Clinical Trials: Pharmaceutical and biotech companies (e.g., Exact Sciences, Daiichi Sankyo, Eli Lilly, Roche/Genentech) sponsor NSABP-designed trials, providing operational funding in exchange for trial execution and data generation.
3. Philanthropy / Charitable Donations: The NSABP Foundation is a 501(c)(3) nonprofit accepting donations from individuals, corporations, and foundations to support its research mission. EIN: 25-1781357.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

NSABP Foundation is an academic research organization (ARO) that designs and conducts Phase II and Phase III clinical trials in breast and colorectal cancer. It operates through a network of more than 500 member sites, maintains a Biospecimen Bank housing specimens from over 87,000 patients, and runs a Translational Pathology Imaging Lab. The organization delivers practice-changing clinical evidence to establish new standards of care and supports pharmaceutical/biotech sponsors with regulatory-grade trial execution within the NCI National Clinical Trials Network (NCTN).

Product overview

NSABP Foundation is an academic research organization (not a technology product company) that designs and conducts clinical trials in breast and colorectal cancer. The organization operates a portfolio of clinical studies including Phase 1-3 trials, a biospecimen bank with specimens from over 87,000 patients, and collaborates with over 500 member sites. The clinical trials program includes named studies such as B-59 (triple-negative breast cancer), B-60 (HER2-positive breast cancer), B-62 CAMBRIA-1 (ER+/HER2- breast cancer), C-14 CORRECT-MRD II (colorectal cancer MRD), and FC-13 EMPIRE (colorectal cancer). Recent research has incorporated multimodal AI models for recurrence risk prediction and circulating tumor DNA assays for molecular residual disease detection.

Differentiator

Problem solved

Functional benefit

Products and services

• NSABP Breast Cancer Clinical Trials Program Comprehensive portfolio of breast cancer clinical trials spanning Phase 1-3, including studies for hormone receptor-positive, HER2-positive, and triple-negative breast cancer. Includes trials evaluating CDK 4/6 inhibitors, HER2-targeted therapies, immunotherapy, and circulating tumor DNA assays for molecular residual disease detection. Targeted at pharmaceutical sponsors and member site investigators in the academic research community.
• NSABP Colorectal Cancer Clinical Trials Program Colorectal cancer clinical trials including studies for metastatic colorectal cancer, microsatellite stable rectal cancer, and trials using circulating tumor DNA for minimal residual disease detection. Includes studies evaluating targeted therapies, immunotherapy combinations, and novel agents. Targeted at pharmaceutical sponsors and academic member site investigators.
• NSABP B-59 Clinical Trial A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer followed by Adjuvant Continuation of Atezolizumab or Placebo. The trial has enrolled 1,550 of 1,520 target patients.
• NSABP C-14 CORRECT-MRD II Clinical Trial Second colorectal cancer clinical validation study to predict recurrence using a circulating tumor DNA assay to detect Minimal Residual Disease. The trial has enrolled 1,015 of 1,000 target patients with colorectal cancer, in clinical collaboration with Exact Sciences and Fight CRC.
• NSABP B-64 Clinical Trial Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated with Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease. The trial has enrolled 1,087 of 1,800 target patients.
• NSABP B-60 DESTINY-Breast05 Clinical Trial Phase 3 study comparing Trastuzumab Deruxtecan (T-DXd) versus Trastuzumab Emtansine (T-DM1) in patients with high-risk HER2-positive primary breast cancer with residual invasive disease following neoadjuvant therapy. The trial has enrolled 95 of 275 target patients and was featured at ESMO25 Presidential Symposium.
• NSABP B-62 CAMBRIA-1 Clinical Trial Phase III study evaluating extended therapy with Camizestrant (AZD9833) versus standard endocrine therapy in patients with ER+/HER2- early breast cancer at intermediate or high risk of recurrence. The trial has enrolled 425 of 430 target patients.
• NSABP FC-13 EMPIRE Clinical Trial Phase II platform study evaluating Cemiplimab monotherapy or Cemiplimab plus Fianlimab in patients with colorectal cancer with Minimal Residual Disease following definitive surgery and chemotherapy. The trial is recruiting with 8 of 57 target patients enrolled.
• NSABP Biospecimen Bank Biospecimen repository housing specimens from more than 87,000 patients, serving as an open resource to the scientific community for research into prognostic or predictive tests. Located at the Nova Place campus in Pittsburgh and available to academic researchers and pharmaceutical sponsors.

Quantifiable outcome

• Breast-conserving surgery (lumpectomy + radiation) established over radical mastectomy, saving millions of patients from unnecessary mutilation
• +6 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature3 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• ECOG-ACRIN Cancer Research GroupcoreStrategic or Co-development Partner · 6 August 2026ECOG-ACRIN partnered with Caris Life Sciences and NRG Oncology to conduct a study published in Cancer Research Communications demonstrating that a multimodal AI model can predict late distant recurrence risk in hormone receptor-positive early breast cancer, using patient data from the NSABP B-42 and TAILORx clinical trials.
• NRG OncologycoreStrategic or Co-development Partner · 6 August 2026NRG Oncology partnered with ECOG-ACRIN and Caris Life Sciences on the multimodal AI study for predicting late distant recurrence in HR+ early breast cancer. NSABP Foundation operates as a member foundation of NRG Oncology within the NCI NCTN.
• Caris Life SciencesminorStrategic or Co-development Partner · 6 August 2026Caris Life Sciences partnered with ECOG-ACRIN and NRG Oncology to conduct and publish the multimodal AI study for late distant recurrence prediction in HR+ early breast cancer, published in Cancer Research Communications.
• German Breast GroupcoreStrategic or Co-development Partner · 11 December 2025The German Breast Group partnered with Exact Sciences and NSABP Foundation on the Oncodetect MRD test clinical study in early triple-negative breast cancer (NSABP B-59 substudy, 147 patients), presented at the San Antonio Breast Cancer Symposium 2025.
• Exact SciencescoreStrategic or Co-development Partner · 14 September 2021NSABP Foundation and Exact Sciences entered a clinical collaboration to conduct the CORRECT-MRD II study (NSABP C-14), validating Exact Sciences' circulating tumor DNA test to detect minimal residual disease and predict cancer recurrence in colorectal cancer patients. Fight CRC also collaborated to help inform study design and support recruitment from diverse populations.
• Alliance for Clinical Trials in OncologycoreStrategic or Co-development PartnerThe Alliance for Clinical Trials in Oncology is one of four research groups within the NCI National Clinical Trials Network (NCTN), alongside NRG Oncology (of which NSABP is a member). They share infrastructure and collaborative trial opportunities within the NCTN framework.
• SWOG Cancer Research NetworkcoreStrategic or Co-development PartnerSWOG is one of the five NCTN research groups. As part of the NCTN, SWOG collaborates with NSABP Foundation member groups (via NRG Oncology) on multi-group clinical trials and translational research.
• Canadian Cancer Trials GroupminorStrategic or Co-development PartnerThe Canadian Cancer Trials Group (CCTG) is an NCTN-affiliated international cooperative oncology group that collaborates on clinical trial design and execution with US-based NCTN groups including those affiliated with NSABP.
• Fight Colorectal CancerminorGTM or Marketing PartnerFight CRC partnered with NSABP Foundation and Exact Sciences to help inform the design of the CORRECT-MRD II study (NSABP C-14) and support recruitment of patients from different racial, ethnic, and underserved populations.
• Cancer Trials Support Unit (CTSU)coreStrategic or Co-development PartnerThe CTSU, a service of the NCI, facilitates access to NCI-funded clinical trials for qualified clinical sites and supports the management and conduct of those trials. NSABP trials are accessible through the CTSU infrastructure.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• NRG Oncology: NSABP Foundation is a member foundation of NRG Oncology and shares infrastructure, member sites, and NCI NCTN funding. NRG is the umbrella cooperative group through which NSABP delivers its phase II/III breast and colorectal trials, making it the closest peer.
• ECOG-ACRIN Cancer Research Group: A fellow NCI NCTN cooperative group running independent phase II/III oncology trials through a parallel academic site network. ECOG-ACRIN is a direct co-author and data partner with NSABP (e.g., TAILORx, B-42 multimodal AI study).
• SWOG Cancer Research Network: One of the five NCI NCTN research groups; runs large multi-site cooperative oncology trials and shares cross-group trial infrastructure with NSABP/NRG. Comparable mission in adult oncology practice-changing trials.
• Alliance for Clinical Trials in Oncology: Another NCI NCTN cooperative oncology group with a comparable academic research organization structure, member site network, and NCI-funded trial portfolio. Directly comparable in operating model and scale.
• German Breast Group (GBG): A European academic research organization focused exclusively on breast cancer trials, comparable in therapeutic focus and ARO model to NSABP. GBG actively co-publishes and co-designs trials with NSABP (e.g., NSABP B-59 Oncodetect substudy).
• Canadian Cancer Trials Group (CCTG): International NCTN-affiliated cooperative oncology group with academic structure similar to NSABP. Collaborates with NSABP/NRG on multi-group trials and provides non-US site reach.
• International Breast Cancer Study Group (IBCSG): A long-established academic cooperative group running international breast cancer trials with a similar non-profit ARO model. Comparable in therapeutic focus (breast), member site approach, and Big Trial leadership profile.

Emerging players

• Breast International Group (BIG): A network of academic breast cancer trial groups that coordinates cross-continent trials. Overlaps with NSABP in breast cancer trial design and investigator networks but operates as a coordinating consortium rather than a single trial sponsor.
• I-SPY 2 Consortium: Adaptive platform trial in neoadjuvant breast cancer run by an academic consortium. Comparable in breast cancer focus and academic ARO leadership but uses a distinctive adaptive platform model versus NSABP's traditional phase III approach.

Broad incumbents

• Children's Oncology Group (COG): Largest NCI-supported pediatric cooperative group; runs multi-site academic oncology trials under an analogous NCTN-aligned ARO model. Comparable in cooperative group structure and NCI funding but addresses a different patient population.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/nsabp/jobs
• Xx.com/nsabpfoundation

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NSABP Foundation